Overview

The analysis explores cutting-edge advancements in non-opioid medications by delving into their mechanisms of action at a molecular scale, scrutinizing results from current clinical research initiatives, and appraising preparedness for and plausibility of regulatory approval. The considerations aim to highlight how these treatments may offer viable pain-managing substitutes to opioids by successfully treating pain through routes other than activating opioid receptors.

Furthermore, we examine ongoing trials on treatments, analyzing their safety and efficacy to shed light on those most likely to obtain authorization from the US Food and Drug Administration (FDA) and fill the need for feasible alternatives.

• How can you capitalize on the growth potential of the effectiveness of various non-opioid options for neuropathic, migraine, and cancer pain management?
• Why are migraine, neuropathic, and cancer pain leading areas of focus for developing novel biologic therapies, and how will they impact growth?
• How can your team grow and gain a competitive edge over innovative biotech companies developing new central and peripheral nervous system-directed therapies?

Quick links

Click here to download the sample of this analysis

Already a member? Click here to access the analysis

Frost Honorarium Program

Unlock a $1,000 Incentive with a Complimentary Growth Dialog

Engage with our industry experts for a discussion to explore new growth opportunities for your business.

As a token of appreciation, you will receive a $1,000 honorarium—redeemable towards any of our products or services.

Schedule Your Growth Dialog Today!